Intestinal thrombotic microangiopathy induced by FK506 in rats.
Thrombotic microangiopathy (TMA) is one of the severe complications after stem cell transplantation (SCT) and is associated with graft-versus-host disease (GVHD) prophylaxis including FK506. In this study, we experimented on rats using FK506 to demonstrate the occurrence of intestinal TMA. FK506 was administrated into Wistar/ST rats intraperitoneally for 7 days. Rats were examined histopathologically after FK506 injection using light and electron microscopy and immunohistochemistry. FK506 concentrations in whole blood were measured by enzyme immunoassay. In the acute phase, hemorrhagic lesions with multifocal erosions and crypt loss were found in the small intestines of all treated rats. Capillary vessels were dilated, and a few platelet thrombi were found. Electron microscopy demonstrated degenerative swelling of endothelial cells and platelet aggregates adhering to the vessel walls. In the later phase, epithelial regenerative failure, characterized by crypt ghosts, was found in the affected mucosa. Apoptotic epithelial cells were increased in number. The extent of intestinal injury was proportional to the whole blood levels of FK506. The intestinal lesions in rats were consistent with TMA and induced by the injection of FK506 alone. Apoptotic enteropathy was also observed and similar to intestinal GVHD. In this study, we established an intestinal TMA model induced by immunosuppressant (Tacrolimus) only without irradiation.
Fujino
M
M
Department of Pathology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Kim
Y
Y
Ito
M
M
D000818:Animals; D017209:Apoptosis; D002196:Capillaries / Q000187:drug effects* / Q000473:pathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006651:Histocytochemistry; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007413:Intestinal Mucosa / Q000098:blood supply* / Q000187:drug effects / Q000473:pathology; D008297:Male; D016491:Peripheral Vascular Diseases / Q000139:chemically induced*; D051381:Rats; D017208:Rats, Wistar; D016559:Tacrolimus / Q000009:adverse effects*; D013927:Thrombosis / Q000139:chemically induced*
D007166:Immunosuppressive Agents; D016559:Tacrolimus